ArticleThoracic cancer2025
Aberrant Hematopoiesis and CD8
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Immunological features of acquired pure red cell aplasia: Specific human leucocyte antigen alleles, signal transducer and activator of transcription 3 mutations and a unique T-cell receptor beta motif.British journal of haematology · 2026Article
- Immune-Mediated Multilineage Cytopenias in Thymoma: A Retrospective Case Series.Thoracic cancer · 2026Article
- Pure Red Cell Aplasia Associated With Thymic Tumors, a Nationwide Retrospective Study.American journal of hematology · 2025Article
- Clinical features and influencing factors analysis of T-cell large granular lymphocytic leukemia complicated with pure red cell aplasia.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThymoma-associated pure red cell aplasia (PRCA) is a rare autoimmune disorder characterized by selective erythroid lineage suppression. However, the underlying immune mechanisms remain unclear.
methodsWe performed single-cell RNA sequencing (scRNA-seq) on bone marrow cells from thymoma-PRCA patients and healthy controls to analyze hematopoietic cell populations. Additionally, we conducted bulk RNA sequencing of peripheral blood CD8 + T cells, flow cytometry analysis of CD8 + T-cell activation, and cytokine profiling of bone marrow supernatant.
resultsscRNA-seq revealed a significant reduction in erythroid progenitors (BFU-E, CFU-E, erythroblasts) and an increase in granulocyte-monocyte progenitors (GMP) in thymoma-PRCA patients. Differential gene expression analysis showed upregulation of TMSB10, AREG, and SPN, which are involved in immune modulation and T-cell activation. Bulk RNA sequencing of CD8 + T cells indicated enhanced expression of activation markers (TNFRSF9, CTLA4, IRF4, CD38, MTHFD2) and decreased expression of erythroid-related genes (HBA1, HBA2, HBB). Flow cytometry confirmed an increased CD8 + T-cell population in the bone marrow, with elevated levels of perforin, granzyme B, IFN-γ, and TNF-α. Cytokine analysis further demonstrated increased IFN-γ and TNF-α levels in the bone marrow microenvironment.
conclusionThymoma-PRCA is associated with excessive CD8 + T-cell activation and an inflammatory bone marrow environment, leading to impaired erythropoiesis. These findings provide novel insights into the immune dysregulation underlying thymoma-associated PRCA and may help identify potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.